Cargando…
The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
PURPOSE: Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. PATIENTS AND METHODS: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of succes...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516197/ https://www.ncbi.nlm.nih.gov/pubmed/37746114 http://dx.doi.org/10.2147/DDDT.S425860 |
_version_ | 1785109088352337920 |
---|---|
author | Li, Wei Zhao, Jun Hao, Ruiping Wang, Shujuan Chen, Ming Liu, Huijun Qi, Le Hao, Zaijun |
author_facet | Li, Wei Zhao, Jun Hao, Ruiping Wang, Shujuan Chen, Ming Liu, Huijun Qi, Le Hao, Zaijun |
author_sort | Li, Wei |
collection | PubMed |
description | PURPOSE: Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. PATIENTS AND METHODS: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO(2), body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded. RESULTS: Procedure completion was equivalent between groups (P > 0.05). Both induction and awakening times were significantly shorter in the P group (P < 0.05). There were no significant differences in colonoscopy time and discharge time (P > 0.05). The lowest SpO(2) was significantly lower in the P group, while the level of fatigue was higher (P < 0.05). Patient satisfaction was significantly higher in the R group (P < 0.05). Endoscopist satisfaction was significantly higher in the P group (P < 0.05). There were no significant differences in both systolic and diastolic blood pressure between groups except at T5 and T6 (P > 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 (P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 (P < 0.05). Pain on injection was significantly higher in the P group (P < 0.05). CONCLUSION: Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time. |
format | Online Article Text |
id | pubmed-10516197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105161972023-09-23 The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial Li, Wei Zhao, Jun Hao, Ruiping Wang, Shujuan Chen, Ming Liu, Huijun Qi, Le Hao, Zaijun Drug Des Devel Ther Original Research PURPOSE: Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. PATIENTS AND METHODS: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO(2), body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded. RESULTS: Procedure completion was equivalent between groups (P > 0.05). Both induction and awakening times were significantly shorter in the P group (P < 0.05). There were no significant differences in colonoscopy time and discharge time (P > 0.05). The lowest SpO(2) was significantly lower in the P group, while the level of fatigue was higher (P < 0.05). Patient satisfaction was significantly higher in the R group (P < 0.05). Endoscopist satisfaction was significantly higher in the P group (P < 0.05). There were no significant differences in both systolic and diastolic blood pressure between groups except at T5 and T6 (P > 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 (P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 (P < 0.05). Pain on injection was significantly higher in the P group (P < 0.05). CONCLUSION: Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time. Dove 2023-09-18 /pmc/articles/PMC10516197/ /pubmed/37746114 http://dx.doi.org/10.2147/DDDT.S425860 Text en © 2023 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Wei Zhao, Jun Hao, Ruiping Wang, Shujuan Chen, Ming Liu, Huijun Qi, Le Hao, Zaijun The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial |
title | The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial |
title_full | The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial |
title_fullStr | The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial |
title_full_unstemmed | The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial |
title_short | The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial |
title_sort | efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy: a prospective, randomized, controlled clinical trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516197/ https://www.ncbi.nlm.nih.gov/pubmed/37746114 http://dx.doi.org/10.2147/DDDT.S425860 |
work_keys_str_mv | AT liwei theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT zhaojun theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT haoruiping theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT wangshujuan theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT chenming theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT liuhuijun theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT qile theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT haozaijun theefficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT liwei efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT zhaojun efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT haoruiping efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT wangshujuan efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT chenming efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT liuhuijun efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT qile efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial AT haozaijun efficacyandsafetyofremimazolambesylatecombinedwithesketamineforoutpatientcolonoscopyaprospectiverandomizedcontrolledclinicaltrial |